Data updated: Mar 29, 2026

LAURUS

Infectious DiseaseRespiratoryCardiovascular

Generics

LAURUS is a generic drug manufacturer focused on Infectious Disease, Respiratory, Cardiovascular. Key products include EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE.

2018

Since

21

Drugs

-

Trials

274

Approved (2yr)

Key Drugs

SACUBITRIL AND VALSARTAN

AT1 receptor 2 indications · 2024

LOPINAVIR AND RITONAVIR

CYP3A 1 indications · 2016

EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

Top Drug Revenues ProEarly access

Loading...

Revenue Over Time ProEarly access

Loading...

Recent Activity

GABAPENTIN 2026-02-24

GABAPENTIN 2026-02-18

GABAPENTIN 2026-02-17

GABAPENTIN 2026-02-17

GABAPENTIN 2026-02-12

GABAPENTIN 2026-01-29

GABAPENTIN 2026-01-29

OSELTAMIVIR PHOSPHATE 2026-01-22

SEC Filings ProEarly access

Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 33%

2 drugs

Respiratory 33%

2 drugs

Cardiovascular 33%

2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones ProEarly access

Loading...

Patent Cliff ProEarly access

Loading...

Competitors by Therapeutic Area

GE HEALTHCARE specialty

Infectious Disease, Cardiovascular, Respiratory

APOTHECON specialty

Infectious Disease, Cardiovascular, Respiratory

LEDERLE big-pharma

Infectious Disease, Cardiovascular, Respiratory

Novartis big-pharma

Cardiovascular, Respiratory

Merck big-pharma

Infectious Disease, Cardiovascular